Drug Trial Radar · NCT05267262
Study to Evaluate R3R01 in Patients With Alport Syndrome and Patients With Focal Segmental Glomerulosclerosis
Last checked: Nov 19, 2026Latest source record: Sep 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
43
Actual
Start
Jun 15, 2022
Primary completion
May 21, 2025
Study completion Aug 19, 2025
Sponsor
- Lead sponsor
- River 3 Renal Corp.Industry
- Sponsor type
- Industry
- First posted
- Mar 4, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2, Multi-center, Open-Label Study to Assess Safety, Tolerability, Efficacy and Pharmacokinetics of R3R01 in Alport Syndrome Patients with Uncontrolled Proteinuria on ACE/ARB Inhibition and in Patients with Primary Steroid-Resistant Focal Segmental Glomerulosclerosis
Conditions
- Alport Syndrome
- Focal Segmental Glomerulosclerosis
Interventions
R3R01Drug
R3R01 administered orally for 12 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse events (Safety and Tolerability)Time frame: 12 weeks
- Assess change in urine creatinine protein ratioTime frame: 12 weeks
Locations
22 sites in 6 countries. Site status is shown where the registry gives one.
Investigative Site
Los Angeles, California
Investigative site
Boca Raton, Florida
Investigative site
Miami, Florida
Investigative site
Riverview, Florida
Investigative site
Atlanta, Georgia
Investigative site
Boston, Massachusetts
Investigative site
Ann Arbor, Michigan
Investigative site
Minneapolis, Minnesota
Investigative Site
Cary, North Carolina
Investigative site
Cleveland, Ohio
Investigative site
Columbus, Ohio
Investigative site
East Providence, Rhode Island
Investigative Site
Dallas, Texas
Investigative site
Houston, Texas
Investigative site
Brussels, Belgium
Investigative site
Liège, Belgium
Investigative site
Paris, France
Investigative site
Göttingen, Germany
Investigative site
Amsterdam, Netherlands
Investigative site
Nijmegen, Netherlands
Investigative site
Leicester, United Kingdom
Investigative site
Nottingham, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.